Karyopharm Therapeutics: Fourth Quarter Earnings Overview

Karyopharm Therapeutics Reports Fourth Quarter Financial Results

Karyopharm Therapeutics Inc., headquartered in Newton, Massachusetts, announced a net loss of $102.2 million for the fourth quarter.

During this period, the company reported a loss of $5.71 per share. When adjusted for debt-related expenses, the loss was $2.23 per share.

These figures were better than anticipated by analysts, as the consensus estimate from three experts polled by Zacks Investment Research predicted a loss of $2.26 per share.

The pharmaceutical firm generated $34.1 million in revenue for the quarter.

Looking at the full year, Karyopharm Therapeutics recorded a total loss of $196 million, or $17.93 per share, with annual revenue reaching $146.1 million.

The company projects its revenue for the upcoming year to fall between $130 million and $150 million.